Abstract
Tumourigenesis is associated with severe changes in the metabolism of the cells. These changes can be understood as metabolic adaptations to the special metabolic demands of proliferation. Cell proliferation strongly depends on energy and cell building blocks such as nucleic acids, phospholipids and amino acids. In tumours, both energy and cell building blocks are generated in two main pathways: glycolysis and glutaminolysis. In fact, tumour cells are usually characterised by high glycolytic and glutaminolytic capacities. The increased conversion rates in both pathways are caused by an upregulation in the activity of specific enzymes as well as changes in the isoenzyme equipment of the cells. In the following overview, the potential use of tumour-specific metabolic changes for the diagnosis of tumours, as well as for patient follow-up, will be discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmed AS, Dew T, Lawton FG, Papadopoulos AJ, Devaja O, Raju KS, Sherwood RA (2007) M2-PK as a novel marker in ovarian cancer. A prospective cohort study. Eur J Gynaecol Oncol 28:83–88
Castaldo G, Calcagno G, Sibillo R, Cuomo R, Nardone G, Castellano L, Del Vecchio BC, Budillon G, Salvatore F (2000) Quantitative analysis of aldolase A mRNA in liver discriminates between hepatocellular cancer and cirrhosis. Clin Chem 46:901–906
Cooper EH (1994) Neuron-specific enolase. Int J Biol Markers 9:205–210
Demir AS, Erdenen F, Müderrisoglu C, Toros AB, Bektas H, Gelisgen R, Tabak O, Altunoglu E, Uzun H, Huq GA, Aral H (2013) Diagnostic and prognostic value of tumor M2-pyruvate kinase levels in patients with colorectal cancer. Turk J Gastroenterol 24:36–42
Dhar DK, Olde Damink SWM, Brindley JH, Godfrey A, Chapman MH, Sandanayake NS, Andreola F, Mazurek S, Hasan T, Malago M, Pereira SP (2013) Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer. Cancer 119:575–585
Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU (2000) Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 20(6D):4965–4968
Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU (2003) Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 23:851–853
Kaura B, Bagga R, Patel FD (2004) Evaluation of the pyruvate kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 30:193–196
Kumar Y, Tapuria N, Kirmani N, Davidson BR (2007) Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 19:265–276
Lüftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K (2000) Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 20:5077–5082
Mazurek S (2011) Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol 43:969–980
Mazurek S, Grimm H, Oehmke M, Weisse G, Teigelkamp S, Eigenbrodt E (2000) Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res 20:5151–5154
Meng W, Zhu HH, Xu ZF, Cai SR, Dong Q, Pan QR, Zeng SZ, Meng W, Ze-Feng X, Cai S-R, Dong Q, Pan Q-R, Zheng S, Su-Zhan S (2012) Serum M2-pyruvate kinase: a promising non-invasive biomarker for colorectal cancer mass screening. World J Gastrointest Oncol 4:145–151
Moreadith RW, Lehninger AL (1984) Purification, kinetic behaviour and regulation of NAD(P) + malic enzyme of tumor mitochondria. J Biol Chem 259:6222–6227
Nakamura K, Kituta T, Nakamura Y, Nakajima Y, Kobayashi K, Uchida T (1987) PFK inhibition test for cancer detection: clinical applications and mechanisms of PFK inhibition. Cancer Detect Prev 10:37–55
Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW (2003) Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK). Anticancer Res 23:1127–1130
Paus E, Myklebust AT (1996) Expression and interconversion of neuron-specific enolase in patient sera and extract from small-cell lung cancer. Tumour Biol 17:271–280
Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E (2000) Quantitative detection of tumor M2- pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 24:531–535
Shinozaki K, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Abe R, Tateishi Y, Hattori N, Shimada T, Hirasawa H (2009) S-100B and neuron-specific enolase as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation: a systematic review. Crit Care 13:R121
Tonus C, Sellinger M, Koss K, Neupert G (2012) Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol 18:4004–4011
Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D (2005) Tumor type M2 pyruvate kinase (Tu M2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer 117:825–830
Wechsel HW, Petri E, Bichler KH, Feil G (1999) Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 19:2583–2590
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Wien
About this chapter
Cite this chapter
Hardt, P.D. (2015). Enzymes of the Tumour Metabolome in Diagnostic Applications. In: Mazurek, S., Shoshan, M. (eds) Tumor Cell Metabolism. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1824-5_8
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1824-5_8
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1823-8
Online ISBN: 978-3-7091-1824-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)